Summary
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III clinical trial of MDR-001, its AI-designed oral
Source: Financial Post
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
